Lv1
38 积分 2023-02-20 加入
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
18小时前
待确认
Next generation Bruton's tyrosine kinase inhibitors - characterization of in vitro potency and selectivity
20天前
已完结
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
1个月前
已完结
Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study
1个月前
已完结
Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia
1个月前
已完结
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results
1个月前
已完结
SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
1个月前
已完结
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study
1个月前
已完结
Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas
1个月前
已完结
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
